TAU to partner with InnoCan Pharma on revolutionary COVID-19 treatment

Written on |

The technology, which is expected to be administered by inhalation, will be tested on several lung infections

InnoCan Pharma Corporation announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has entered into a sponsored research agreement with Ramot at Tel Aviv University to jointly develop a novel, revolutionary approach to treat COVID-19 by using cannabidiol (CBD) loaded exosomes (“CLX”). Under the terms of the Research Agreement, InnoCan and a team led by Prof. Daniel Offen, a leading researcher specializing in Neuroscience and Exosome technology at Tel Aviv University, will collaborate to develop the cell therapy based product on Prof. Offen’s work in the field. InnoCan and Ramot are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus. CBD-Loaded exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. The techology, which is expected to be administered by inhalation, will be tested on a variety of lung infections. Exosomes are small particles created when stem cells are multiplied. Exosomes can act as “homing missiles” when the cell healing properties of the exosomes are combined with the anti-inflammatory properties of CBD. Exosomes also have an important role in cell-to-cell communication, which can be beneficial to additional treatments for CNS indications such as epilepsy and Alzheimer’s Disease.

Background

The world is suffering from a rapid rise in illness due to the fast growing spread of the COVID-19 pandemic. The lungs are the organ most affected by COVID-19, causing pneumonia that rapidly progresses to acute respiratory distress syndrome and can further result in respiratory failure, septic shock, multi-organ failure, and in the most severe cases death. Recent in-vivo and in-vitro studies have demonstrated that exosomes derived from mesenchymal stem cells (MSC) can promote regeneration and improve immune reaction processes in damaged tissues. Exosomes contain anti-inflammatory agents that can target inflamed organs. Prof. Offen and his team have already successfully loaded exosomes with various molecules. They have also succeeded in treating different tissue injuries in animal models, while significantly reducing inflammation and pathological impairment. To date, there have been hundreds of clinical studies using exosomes globally, demonstrating their therapeutic potential at different applications. Animal studies have also demonstrated CBD as effective in reducing lung inflammation. Based on these findings, InnoCan believes that its CLX therapy has the potential to treat the COVID-19 virus by combining CBD with exosomes, thereby creating therapeutic synergies. The suggested combination may have strong synergetic effects, thereby increasing the potential efficacy of planned treatments. Prof. Dani Offen, of the Sackler School of Medicine and Sagol School of Neuroscience  said, “I am pleased to work with the InnoCan team on this exciting CLX development project. We are facing a challenging time, and I believe our unique approach holds a promise to offer a treatment for COVID-19, pneumonia and perhaps for other lung inflammations as well.” Iris Bincovich, CEO of InnoCan’s CEO, also commented, “COVID-19 has quickly become one of the largest challenges in healthcare today. With the development of CLX, we are creating a new treatment, to join the global mission to combat the effects of COVID-19. We are determined to make a difference as quickly as possible to assist patients worldwide.” Keren Primor Cohen, CEO of Ramot at Tel Aviv University, summarized, “We hope that this collaboration with Innocan will assist in transforming Prof. Offen’s promising technology into a real treatment for the global threat of COVID-19”. Featured image: Prof. Daniel Offen (photo: Jonathan Blum)

related posts

COVID-19 Immunity Varies Among Genders and Age Groups

July 25, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

First-of-its-kind study: Researchers used smart watches to monitor changes in quality of life during lockdowns

June 8, 2021

How Will We Brave the Post-COVID Era?

May 31, 2021

British Variant 45% More Contagious than Original Virus

April 28, 2021

COVID-19 Vaccinations at TAU

March 24, 2021

Covid-19 Vaccination of Nursing Mothers May Protect Babies

March 24, 2021

Academic First Responders

January 14, 2021

TAU Study Proves that Light Can Kill Coronavirus

December 14, 2020

COVID-19 Takes TAU’s Legal Clinics into High Gear

December 7, 2020

Parents show love less during COVID-19: TAU Study

December 2, 2020

Study: Women Suffer More from COVID-related Orofacial Pain

November 12, 2020

Global First: Center for Combating Pandemics

October 22, 2020

TAU Researchers Discover Antibody Combo that Fights COVID-19

October 12, 2020

Immunity Memory Cells Stay Stable Over Time After Recovery From COVID-19

October 12, 2020

Google Awards Competitive Grant to Tel Aviv University for COVID-19 Research

September 15, 2020

TAU Joint Study: COVID-19 Deaths Dive on Weekends

September 10, 2020

TAU Wins 3M Grant to Accelerate COVID-19 Vaccine Development

September 9, 2020

TAU Inaugurates Shmunis School of Biomedicine and Cancer Research

September 8, 2020

New school for Biomedicine and Cancer Research at Tel Aviv University

August 13, 2020

TAU Researcher Invents Environmentally-Friendly Sanitizer

August 11, 2020

TAU Researcher Fights Epidemics Both Viral and Virtual

July 23, 2020

Tel Aviv University presents an analysis of the reaction of human antibodies to the coronavirus

July 5, 2020

TAU Researchers Fighting Covid-19

June 30, 2020

Tel Aviv University’s Serological tests

May 25, 2020

New TAU study tracks coronavirus spread patterns in Israel

May 21, 2020

Coronavirus bootcamp? New serological test conducted with the IDF

May 19, 2020

TAU partners with pharma company to develop COVID-19 vaccine

May 13, 2020

What about the environment?

May 11, 2020

A world first: TAU to establish multidisciplinary Epidemic Research Center

May 11, 2020

Tel Aviv University joins national Coronavirus testing system

May 7, 2020

TAU lab identifies effective antibodies from recovered Coronavirus patients

May 7, 2020

TAU Student, COVID-19 Sprint Invent Disposable Ventilators to Help Treat Coronavirus Patients

April 28, 2020

TAU Scientist Awarded U.S. Patent for Novel Coronavirus Vaccine Design

April 19, 2020

Message from Tel Aviv University President

April 18, 2020

Donated Equipment Aids in Urgent Coronavirus Research

April 6, 2020

Tel Aviv University Sets Up Emergency Lab to Expand COVID-19 Testing

April 5, 2020

Milner Foundation Donates $3 million to Tel Aviv University, Magen David Adom and Tel Aviv Sourasky Medical Center (Ichilov)

March 25, 2020

Students Volunteer to Increase and Improve Coronavirus Testing Across Israel

March 22, 2020

Les étudiants de l’Université de Tel-Aviv participent au combat contre le Coronavirus

March 22, 2020

TAU researcher launches urgent push to beat corona

March 18, 2020

What’s more important? Privacy vs. public health

March 17, 2020
Ontario and Western Canada

3130 Bathurst Street, Suite, 214, Toronto, ON | M6A 2A1 
Phone: 416.787.9930 | Toll Free: 833.32.CFTAU (22328)
Email: toronto@cftau.ca

Ottawa, Quebec and Atlantic Canada

6900 Boulevard Décarie, Suite 3480, Montreal, QC | H3X 2T8
Phone: 514.344.3417
Email: montreal@cftau.ca


© CFTAU  | all rights reserved
Charitable registration: 124035643RR0001

TO TOP